ライフサイエンスコーパス: partial thromboplastin time

1 nogen level, prothrombin time, and activated partial thromboplastin time.

2 ad no effect on the TF-independent activated partial thromboplastin time.

3 , platelets, prothrombin time, and activated partial thromboplastin time.

4 time and, at higher doses, of the activated partial thromboplastin time.

5 tithrombin III, platelet count, or activated partial thromboplastin time.

6 y and a marked prolongation of the activated partial thromboplastin time.

7 gatroban, adjusted to maintain the activated partial thromboplastin time 1.5 to 3.0 times baseline va

8 og x kg x min, adjusted to achieve activated partial thromboplastin times 1.5-3 times baseline

9 ng victims had a three-fold longer activated partial thromboplastin time (124 s; p<0.001) than both n

10 ; p = 0.004), daily geometric mean activated partial thromboplastin time (48.1 s [95% CI, 43.5-53.2 s

11 doses of heparin (n = 50) (target activated partial thromboplastin time, 65 to 90 seconds or 90 to 1

12 cytopenia (13% and 23%); prolonged activated partial thromboplastin time (8% and 18%); elevated aspar

13 mbin generation, prothrombin time, activated partial thromboplastin time, activated clotting time, an

14 es in thrombin generation, prothrombin time, partial thromboplastin time, activated clotting time, R+

15 No relationship was seen with activated partial thromboplastin time, activated protein C resista

16 -factor Xa activity but comparable activated partial thromboplastin time activity.

17 profiles (index normalized ratio, activated partial thromboplastin time) after reperfusion were simi

18 These functional studies and activated partial thromboplastin time analysis validate prediction

19 e eliminating more than 90% of its activated partial thromboplastin time and anti-factor Xa activity.

20 gnificant difference in mean daily activated partial thromboplastin time and anti-Xa levels between g

21 t pathway components prolonged the activated partial thromboplastin time and decreased target protein

22 but was associated with prolonged activated partial thromboplastin time and extravascular hemorrhage

23 bust and sustained prolongation of activated partial thromboplastin time and FXI suppression for up t

24 ion between the peak posttreatment activated partial thromboplastin time and post hoc weight-adjusted

25 the permissive range and returned activated partial thromboplastin time and prothrombin time clottin

26 Plasma activated partial thromboplastin time and prothrombin time increas

27 Activated partial thromboplastin time and prothrombin time were sh

28 The activated partial thromboplastin time and prothrombin time, as wel

29 Exposure-dependent prolongation of activated partial thromboplastin time and reduction of FXI clottin

30 ability of heparin to prolong the activated partial thromboplastin time and the factor Xa- one-stage

31 I-like activity in assays (diluted activated partial thromboplastin time and thrombin generation), si

32 ogen reduction treatment increased activated partial thromboplastin time and thrombin time, while red

33 Klkb1(-/-) plasmas have long-activated partial thromboplastin times and defective contact activ

34 Coagulation was assessed using activated partial thromboplastin times and prothrombin times.

35 vels and increased prothrombin and activated partial thromboplastin times and tissue factor, tissue f

36 ssays of thrombosis in vitro (e.g. activated partial thromboplastin time) and in vivo (e.g. rat FeCl(

37 ts, fibrinogen, prothrombin index, activated partial thromboplastin time, and d-dimer as well as the

38 high D-dimer, prolonged prothrombin time and partial thromboplastin time, and falling fibrinogen) res

39 platelets and increases of prothrombin time, partial thromboplastin time, and fibrin split products.

40 , whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are rel

41 count, bleeding, fibrinogen level, activated partial thromboplastin time, and somnolence.

42 f the activated clotting time, the activated partial thromboplastin time, and the cuticle bleeding ti

43 had a linear correlation with the activated partial thromboplastin time (aPTT) (r = 0.99).

44 ant effect as assessed by anti-Xa, activated partial thromboplastin time (aPTT) and activated clottin

45 The activated partial thromboplastin time (aPTT) and anti-factor X (an

46 The activated partial thromboplastin time (APTT) and prothrombin time

47 Activated partial thromboplastin time (aPTT) and prothrombin time

48 by comparing the PA signal to the activated partial thromboplastin time (aPTT) as well as the activa

49 FIX21D had reduced activity in an activated partial thromboplastin time (aPTT) assay and was activat

50 coagulation and is captured by the activated partial thromboplastin time (aPTT) assay.

51 has relatively normal activity in activated partial thromboplastin time (aPTT) assays.

52 arin group without prolongation of activated partial thromboplastin time (aPTT) before and after the

53 ctivity as measured by a one-stage activated partial thromboplastin time (aPTT) clotting assay (36% +

54 C mutants were characterized using activated partial thromboplastin time (APTT) clotting assays and F

55 Finally, the activated partial thromboplastin time (aPTT) coagulation assay was

56 We examined the activated partial thromboplastin time (aPTT) in 29,656 patients in

57 ponse to infusion of thrombin, the activated partial thromboplastin time (APTT) increased by 11+/-3 s

58 Reduced activated partial thromboplastin time (aPTT) is a risk marker for

59 Activated partial thromboplastin time (aPTT) is associated with ri

60 d ratio (INR) greater than 1.4, or activated partial thromboplastin time (APTT) longer than 39 second

61 specimens were tested for modified activated partial thromboplastin time (aPTT) measured on an optica

62 rolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) obtained before elect

63 th short prothrombin time (PT) and activated partial thromboplastin time (APTT) of 14.2 and 35.5s res

64 hrombins were titrated to a target activated partial thromboplastin time (aPTT) of 55 to 85 seconds a

65 s, frozen thawed washed platelets, activated partial thromboplastin time (aPTT) reagent and prothromb

66 easure the clotting time using the activated partial thromboplastin time (APTT) test.

67 Site-specific validation of the activated partial thromboplastin time (aPTT) therapeutic range is

68 ational normalized ratio (INR) and activated partial thromboplastin time (aPTT) values were 1.5 and 4

69 Additional association with activated partial thromboplastin time (aPTT) was tested for the to

70 ong both the thrombin time and the activated partial thromboplastin time (aPTT) when added to normal

71 essure (DeltaSBP), platelet count, activated partial thromboplastin time (APTT), and injury severity

72 lted in complete correction of the activated partial thromboplastin time (aPTT), and that injection o

73 , including prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (T

74 (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (T

75 Increases in activated partial thromboplastin time (aPTT), anti-factors IIa and

76 ite activated clotting time (ACT), activated partial thromboplastin time (APTT), heparin concentratio

77 onding CCTs [prothrombin time (PT)/activated partial thromboplastin time (aPTT), international normal

78 We tested the activated partial thromboplastin time (APTT), international normal

79 ignificant 43% prolongation of the activated partial thromboplastin time (aPTT), over controls (P < 0

80 We measured ACT (Hemochron), activated partial thromboplastin time (aPTT), plasma anti-Xa and a

81 in at doses that significantly prolonged the partial thromboplastin time (APTT), prothrombin time (PT

82 eases were studied for their blood activated partial thromboplastin time (APTT), prothrombin time (PT

83 , including prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT),

84 ent than ATS-112 in prolonging the activated partial thromboplastin time (APTT), whereas ATS-119 inhi

85 tivated coagulation time (ACT) and activated partial thromboplastin time (aPTT).

86 frequently combined with tests for activated partial thromboplastin time (aPTT).

87 ity) and a concomitant increase in activated partial thromboplastin time (APTT).

88 The activated partial thromboplastin time (APTT; baseline, 28 seconds)

89 resistance ratio values (ratio of activated partial thromboplastin time [APTT] clotting times with a

90 activated clotting time [ACT], and activated partial thromboplastin time [aPTT]) have remained at the

91 while the acoustic assays namely ''activated Partial Thromboplastin Time'' (aPTT) and ''Prothrombinas

92 fewer than 35% of patients having activated partial thromboplastin times (aPTTs) within a range of 5

93 nomogram with centrally monitored activated partial thromboplastin times (aPTTs).

94 increased liver enzymes, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-1

95 n factor XI deficient plasma in an activated partial thromboplastin time assay, with a specific activ

96 uction in specific activity in the activated partial thromboplastin time assay.

97 prolonged the clotting time in an activated partial thromboplastin time assay.

98 stern blots, prothrombin time, and activated partial thromboplastin time assays and fibrinopeptide A

99 otein C (APC) cofactor activity in activated partial thromboplastin time assays in PS-depleted plasma

100 ng activity in modified prothrombin time and partial thromboplastin time assays, respectively.

101 2%, 53%, and <5%, respectively, in activated partial thromboplastin time assays.

102 ctive in both prothrombin time and activated partial thromboplastin time assays; however, it exhibite

103 time dose dependently; the median activated partial thromboplastin time at 10 minutes after a single

104 oubled activated clotting time and activated partial thromboplastin time at the higher dose.

105 reated FV was analyzed in an aPTT (activated partial thromboplastin time)-based APC sensitivity assay

106 r = 0.47, P = 0.035), but not with activated partial thromboplastin time-based APC resistance ratios.

107 ticoagulation with heparin (target activated partial thromboplastin time between 50 and 70 s) or lowe

108 difference in daily geometric mean activated partial thromboplastin time between groups when consider

109 reover, fibrinogen, platelets, and activated partial thromboplastin time (but not prothrombin index)

110 ane bound TF, and has no effect on activated partial thromboplastin time, but is 70-fold less potent

111 as measured in a factor VIII-based activated partial thromboplastin time clot assay.

112 tectable anticoagulant activity in activated partial thromboplastin time clotting assays but retained

113 In activated partial thromboplastin time clotting assays, the specifi

114 P < 0.05) more rapidly and exhibited shorter partial thromboplastin times compared with HP controls.

115 ements of laboratory-based prothrombin time, partial thromboplastin time, complete blood count, and b

116 with impaired liver function, and activated partial thromboplastin time confounding may interfere wi

117 and a non-linear relationship with activated partial thromboplastin time; curves were similar to thos

118 e, international normalized ratio, activated partial thromboplastin time, d-dimers, factor VIII coagu

119 ned bleeding time, decreased prothrombin and partial thromboplastin times (decreased plasma clotting

120 Patients with prolonged partial thromboplastin times did not have a statisticall

121 RB006 increased the activated partial thromboplastin time dose dependently; the median

122 nitoring with both the anti-Xa assay and the partial thromboplastin time due to cirrhosis-related ant

123 The activated partial thromboplastin time, factor VIII activity, von-W

124 atelet counts, with plasma prothrombin time, partial thromboplastin time, fibrinogen levels, fibrin s

125 rs by changes in prothrombin time, activated partial thromboplastin time, fibrinogen, fibrinogen-fibr

126 In contrast, activated partial thromboplastin time for 7.5% NaCl adenocaine/Mg(

127 cyte count (five [12%]), prolonged activated partial thromboplastin time (four [10%]), and decreased

128 ated patients achieved therapeutic activated partial thromboplastin times generally within 4 to 5 hou

129 present a parallel anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algor

130 Longer activated partial thromboplastin time (hazards ratio, 0.98; p = 0.

131 to explain the prolongation of the activated partial thromboplastin time identified in patients with

132 gation of the prothrombin time and activated partial thromboplastin time in affected individuals.

133 oagulation factor XII activity and activated partial thromboplastin time in heparinase-treated sample

134 mpound 32 caused a doubling of the activated partial thromboplastin time in human plasma at 2.4 micro

135 onucleotides (PS ODNs) prolong the activated partial thromboplastin time in human plasma by inhibitio

136 Test performance characteristics for the partial thromboplastin time in predicting postoperative

137 Prolongation of activated partial thromboplastin time in streptococcal toxic shock

138 ed lymphocyte count, and prolonged activated partial thromboplastin time in the soft-tissue sarcoma g

139 ncreases both prothrombin time and activated partial thromboplastin time in vitro or ex vivo.

140 thesis, prolonged prothrombin, and activated partial thromboplastin times, in whom no classifying dia

141 se) and coagulation times (prothrombin time, partial thromboplastin time) indicated that iNO improved

142 lly if the baseline (pretreatment) activated partial thromboplastin time is prolonged.

143 eutic bivalirudin anticoagulation (activated partial thromboplastin time less than twice the control

144 00, 500, or 2500 units/kg produced activated partial thromboplastin time levels less than, within, or

145 n (up to 12,000 U/24 hr aiming for activated partial thromboplastin time < 45 s).

146 sorium, low serum albumin concentration, and partial thromboplastin time < or =25 seconds predict a h

147 sorium, low serum albumin concentration, and partial thromboplastin time < or =25 seconds.

148 uch as coagulation variables (mean activated partial thromboplastin time <= 50 s, international norma

149 ific gravity, magnesium, globulin, activated partial thromboplastin time, lymphocyte count (L%), and

150 to sepsis, heparin titrated using activated partial thromboplastin times may be efficacious.

151 or alpha-2-macroglobulin (A2M) and activated partial thromboplastin time measurement for coagulation

152 ne oxygenation, which may confound activated partial thromboplastin time measurements and limit its c

153 macodynamic response, reflected in activated partial thromboplastin time measurements, was seen after

154 tients) that compared therapeutic (activated partial thromboplastin time more than twice the control

155 fter the first dose of emicizumab, activated partial thromboplastin time normalized in 1 to 3 days, F

156 er LMW-DS or heparin, targeting an activated partial thromboplastin time of 150 +/- 10 seconds and 50

157 international normalized ratio of 1.2, and a partial thromboplastin time of 29.3 seconds.

158 296), which consisted of a target activated partial thromboplastin time of 45 to 60 seconds, for con

159 atory studies revealed a prolonged activated partial thromboplastin time of 49.2 seconds, a normal pr

160 15H8 prolonged the activated partial thromboplastin time of baboon and human plasmas.

161 The activated partial thromboplastin time of the treated mice was full

162 g., d-dimer, fibrinogen level, and activated partial thromboplastin time) or inflammation (WBC count,

163 /kg with E. coli further increased activated partial thromboplastin time (p < .0001 vs. placebo) with

164 ), prothrombin time (p < .02), and activated partial thromboplastin time (p < .05).

165 (i.e., with placebo) increased the activated partial thromboplastin time (p = .002) close to the ther

166 nal normalized ratio (p = 0.99) or activated partial thromboplastin time (p = 0.29).

167 e reversion (P=0.04), higher final activated partial thromboplastin time (P=0.05), lower final von Wi

168 Severe activated partial thromboplastin time prolongation may be a marker

169 Grade I post-partial thromboplastin time prolongations were noted.

170 (p < 0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2

171 nd international normalized ratio, activated partial thromboplastin time, prothrombin activity, throm

172 tory, use of respiratory supports, activated partial thromboplastin time, prothrombin time, and deep

173 Mean activated partial thromboplastin time, prothrombin time, and inter

174 changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the fir

175 Ocular examinations, virus isolation, and partial thromboplastin time (PTT) were evaluated during

176 on indices, including prothrombin time (PT), partial thromboplastin time (PTT), and D-dimer concentra

177 evere injury, prolonged prothrombin time and partial thromboplastin time (PTT), and lower levels of b

178 Prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen/fibrin deg

179 ective, linear prolongation of the activated partial thromboplastin time (PTT).

180 XII activity correlated well with activated partial thromboplastin time (r = -0.789; p = 0.007).

181 ed ratio (r=0.72) but less so with activated partial thromboplastin time (r=0.56; all P<0.001).

182 nt of heparin required to maintain activated partial thromboplastin time ratio 1.5-2.

183 the percentage of patients with an activated partial thromboplastin time ratio greater than 1.8 (47.8

184 s (71.4%) despite it having a mean activated partial thromboplastin time ratio of 1.60 +/- 0.31.

185 The mean activated partial thromboplastin time ratio was higher in the seve

186 1.19; reference value, 0.80-1.25; activated partial thromboplastin time ratio, 0.88 second; referenc

187 e and prothrombin time, as well as activated partial thromboplastin time reagent and tissue factor-in

188 en the dose of heparin was decreased and the partial thromboplastin time returned towards the normal

189 minogen activator inhibitor 1, and activated partial thromboplastin time showed variability but no si

190 in time, international normalized ratio, and partial thromboplastin time testing after a best practic

191 The treated mice exhibited activated partial thromboplastin times that were comparable to tho

192 and APC-dependent prolongation of activated partial thromboplastin times that were two- to three-fol

193 rements included prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen,

194 d prolonged prothrombin time to 113% +/- 2%, partial thromboplastin time to 122% +/- 4%, activated cl

195 RB007 reversed the activated partial thromboplastin time to baseline levels within a

196 se levels) and sustained return of activated partial thromboplastin time to within the normal range.

197 L, fibrinogen level <60 mg/dL, and activated partial thromboplastin time values >100 seconds were the

198 At 60-min resuscitation, activated partial thromboplastin time values for untreated, 7.5% N

199 se cases were associated with subtherapeutic partial thromboplastin time values.

200 Baseline plasma activated partial thromboplastin time was 17+/-0.5 secs and increa

201 the mean dose was 588 units/hr, and the mean partial thromboplastin time was 37 secs.

202 nificant, dose-related increase in activated partial thromboplastin time was accompanied by a trend t

203 Prolongation of activated partial thromboplastin time was associated with reduced

204 o gamma-thrombin was inhibited and activated partial thromboplastin time was increased after treatmen

205 Partial thromboplastin time was increased six- to sevenf

206 The activated partial thromboplastin time was prolonged in only the rT

207 The activated partial thromboplastin time was prolonged to a similar e

208 The activated partial thromboplastin time was unchanged.

209 Prolongation of prothrombin and partial thromboplastin times was accompanied by evidence

210 asma and both prothrombin time and activated partial thromboplastin time were normal.

211 levels were normal, but prothrombin time and partial thromboplastin time were prolonged and bone alka

212 Lower values for Quick's test and higher partial thromboplastin times were associated with a high

213 Systemic partial thromboplastin times were not affected by local

214 ncentrations and increase in prothrombin and partial thromboplastin times were significantly attenuat

215 ococcal necrotizing fasciitis, the activated partial thromboplastin times were significantly prolonge

216 od clotting times were normalized, activated partial thromboplastin times were substantially reduced,

217 lot formation time, T(GP), and the activated partial thromboplastin time, whereas the association of

218 cynomolgus monkeys as assessed by activated partial thromboplastin time without any evidence of blee